Document is current

Article History

Received: 21 March 2025

Accepted: 2 July 2025

First Online: 25 July 2025

Declarations

:

: This study uses anonymised data collected by NHS centres as part of routine care. The contributing centres to this study were Oxford University Hospital NHS Foundation Trust, Chelsea and Westminster Hospital NHS Foundation Trust, Hampshire Hospitals NHS Foundation Trust and NHS Greater Glasgow and Clyde.The study was submitted to and approved by the Local Privacy Advisory Committee of the West of Scotland Safe Haven research database at NHS Greater Glasgow and Clyde under NHS Research Ethics Committee (REC) approval 22/WS/0163, and adheres to the Declaration of Helsinki. Informed consent was not collected for the study as UK law (UK GDPR and the Data Protection Act 2018) does not require consent for the collection and processing of anonymised data.

: Not applicable.

: CT, TP and SW are employees of Pfizer and may hold stock or stock options. CD was an employee of Pfizer at the time of the study and may hold stock or stock options. JOR, LC, FT, JW, AP are employees of Arcturis Data Limited which received funds from Pfizer to conduct the study and develop the manuscript. LC has also received personal consulting fees from Pfizer and is a member for a safety monitoring board for the George Institute for Global Health. KR has received research support from Celgene (BMS), Takeda, Janssen, Amgen and GSK; speaker fees from Celgene, Takeda, Sanofi, EUSA Pharma/Recordati Rare Diseases, Menarini Stemline, Janssen, Pfizer and GSK; advisory board support from Celgene, Takeda, Janssen, Amgen, AbbVie, Sanofi, Oncopeptides, Karyopharm, GSK, EUSA Pharma/Recordati Rare Diseases and Pfizer; and travel fees from Takeda, Amgen and Menarini Stemline.